NanoViricides to Present Anti-Dengue Drug Candidates Results at Dengue Research Conference

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") has been invited to present at the meeting “A Re-Emerging Challenge in the Americas: Opportunities for Dengue Research Collaborations” sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) to be held February 15-18, 2011 in San Juan, Puerto Rico. The Company will present the results of its anti-Dengue drug candidates.

The objective of this prestigious meeting is to provide a forum to promote and stimulate new or enhanced research collaborations in the Americas for the development of diagnostics, therapeutics and vaccines. The Company has previously reported that its anti-Dengue nanoviricide® drug candidates demonstrated significant protection in animal survival studies of Dengue virus infection in a collaboration with the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley (UC Berkeley). Dr. Harris, as well as Dr. Harold Margolis, Chief of the Dengue Branch of the CDC, will also be attending the meeting.

Dengue is endemic in Mexico, the Caribbean, Central America, as well as many countries in South America, and is a rising infection in all tropical countries. Dengue infections have occurred in the southern US states, and travel leads to sporadic cases of dengue in the USA. According to WHO, dengue threatens over 40% of the world population.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback